04/21/2026
The FDA just signaled a meaningful shift on compounded peptides. For brain medicine, that matters more than most people realize.
For three years, patients asking about BPC-157, Cerebrolysin, DSIP, and Dihexa were sourcing them from research-chemical vendors. Some of those vials tested under forty percent purity. The ban did not reduce use. It pushed demand offshore.
Now that prohibition is unwinding, and licensed pharmacies will eventually be able to produce these molecules for specific indications. Dr. Sean Orr on why this is a patient-safety win, what the real timeline looks like, and which peptides neurologists should be paying attention to.
Full article → https://neurogenesisproject.com/blog/peptides-brain-medicine
Is peptide therapy something you have been asking your physician about?